These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 18991958)

  • 21. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations.
    Villemagne V; Yuan J; Wong DF; Dannals RF; Hatzidimitriou G; Mathews WB; Ravert HT; Musachio J; McCann UD; Ricaurte GA
    J Neurosci; 1998 Jan; 18(1):419-27. PubMed ID: 9412518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron emission tomography radioligands for dopamine transporters and studies in human and nonhuman primates.
    Volkow ND; Fowler JS; Ding YS; Wang GJ; Gatley SJ
    Adv Pharmacol; 1998; 42():211-4. PubMed ID: 9327881
    [No Abstract]   [Full Text] [Related]  

  • 23. Translational neuroimaging in drug addiction and obesity.
    Michaelides M; Thanos PK; Volkow ND; Wang GJ
    ILAR J; 2012; 53(1):59-68. PubMed ID: 23520600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Environmental modulation of drug taking: Nonhuman primate models of cocaine abuse and PET neuroimaging.
    Nader MA; Banks ML
    Neuropharmacology; 2014 Jan; 76 Pt B(0 0):510-7. PubMed ID: 23748095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From vice to virtue: insights from sensitization in the nonhuman primate.
    Castner SA; Williams GV
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Nov; 31(8):1572-92. PubMed ID: 17904719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging neurotransmitter release by drugs of abuse.
    Martinez D; Narendran R
    Curr Top Behav Neurosci; 2010; 3():219-45. PubMed ID: 21161755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What have positron emission tomography and 'Zippy' told us about the neuropharmacology of drug addiction?
    Cumming P; Caprioli D; Dalley JW
    Br J Pharmacol; 2011 Aug; 163(8):1586-604. PubMed ID: 20846139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Similarities and Differences in Neuroimaging.
    Sun YK; Sun Y; Lin X; Lu L; Shi J
    Adv Exp Med Biol; 2017; 1010():73-89. PubMed ID: 29098669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug dependence and addiction, III: Expectation and brain function in drug abuse.
    Volkow N
    Am J Psychiatry; 2004 Apr; 161(4):621. PubMed ID: 15056504
    [No Abstract]   [Full Text] [Related]  

  • 30. Monoamine transporter inhibitors and substrates as treatments for stimulant abuse.
    Howell LL; Negus SS
    Adv Pharmacol; 2014; 69():129-76. PubMed ID: 24484977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cocaine, metamfetamine, and MDMA abuse: the role and clinical importance of neuroadaptation.
    Seger D
    Clin Toxicol (Phila); 2010 Aug; 48(7):695-708. PubMed ID: 20849328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Japan Monkey Centre Primates Brain Imaging Repository of high-resolution postmortem magnetic resonance imaging: The second phase of the archive of digital records.
    Sakai T; Hata J; Shintaku Y; Ohta H; Sogabe K; Mori S; Miyabe-Nishiwaki T; Okano HJ; Hamada Y; Hirabayashi T; Minamimoto T; Sadato N; Okano H; Oishi K
    Neuroimage; 2023 Jun; 273():120096. PubMed ID: 37031828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging receptor changes in human drug abusers.
    Cosgrove KP
    Curr Top Behav Neurosci; 2010; 3():199-217. PubMed ID: 21161754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical PET Neuroimaging of [11C]Bexarotene.
    Rotstein BH; Placzek MS; Krishnan HS; Pekošak A; Collier TL; Wang C; Liang SH; Burstein ES; Hooker JM; Vasdev N
    Mol Imaging; 2016; 15():. PubMed ID: 27553293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The application of neuroimaging techniques to drug development.
    Tamminga CA; Conley RR
    J Clin Psychiatry; 1997; 58 Suppl 10():3-6. PubMed ID: 9265909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From rats to humans and return: testing addiction hypotheses by combined PET imaging and self-reported measures of psychostimulant effects. Commentary on Volkow et al. 'Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies'.
    Di Chiara G
    Behav Pharmacol; 2002 Sep; 13(5-6):371-7. PubMed ID: 12394413
    [No Abstract]   [Full Text] [Related]  

  • 37. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.
    Narendran R; Slifstein M; Guillin O; Hwang Y; Hwang DR; Scher E; Reeder S; Rabiner E; Laruelle M
    Synapse; 2006 Dec; 60(7):485-95. PubMed ID: 16952157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An apparatus and behavioral training protocol to conduct positron emission tomography (PET) neuroimaging in conscious rhesus monkeys.
    Howell LL; Hoffman JM; Votaw JR; Landrum AM; Jordan JF
    J Neurosci Methods; 2001 Apr; 106(2):161-9. PubMed ID: 11325436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs.
    Cunha-Oliveira T; Rego AC; Oliveira CR
    Brain Res Rev; 2008 Jun; 58(1):192-208. PubMed ID: 18440072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and Preclinical Validation of [(11)C]AZ13153556, a Novel Probe for the Histamine Type 3 Receptor.
    Schou M; Varnäs K; Jureus A; Ahlgren C; Malmquist J; Häggkvist J; Tari L; Wesolowski SS; Throner SR; Brown DG; Nilsson M; Johnström P; Finnema SJ; Nakao R; Amini N; Takano A; Farde L
    ACS Chem Neurosci; 2016 Feb; 7(2):177-84. PubMed ID: 26529287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.